Abstract: Provided are an RNA plasmid delivery system and an application thereof. The RNA plasmid delivery system comprises a plasmid carrying an RNA fragment required to be delivered; the plasmid can be enriched in an organ tissue of a host, and spontaneously forms an exosome containing the RNA fragment in the organ tissue of the host, and therefore can enter and be combined with a target tissue to deliver the RNA fragment into the target tissue. The RNA delivery system is safe, reliable, good in druggability, and strong in universality.

Abstract: Provided are a gene circuit, an RNA delivery system and the use thereof. Specifically, the gene circuit comprises at least an RNA fragment capable of inhibiting gene expression and/or a targeting tag having a targeting function. The gene circuit can be delivered to a host, enriched in organ tissues of the host and self-assembled to form a complex structure, and inhibits gene expression by means of the RNA fragment, thereby treating diseases. The delivery system comprises the gene circuit and a delivery carrier capable of delivering the gene circuit to organ tissues of a host for enrichment. The provided gene circuit has a targeting function and a treatment function, can quickly and accurately reach target organs and target tissues to exert a treatment effect, and is highly efficient with good results. The safety and reliability of the provided RNA delivery system are fully verified, and the RNA delivery system has good druggability, high universality, and great economic benefits and application prospects.

Abstract: An RNA delivery system for the treatment of Huntington's disease. The system comprises a viral vector, the viral vector carries RNA fragments capable of treating Huntington's disease, the viral vector is capable of enrichment in organ tissues of a host and endogenously and spontaneously forming a complex containing the RNA fragments capable of treating Huntington's disease in the organ tissues of the host, and the complex can deliver the RNA fragments into a target tissue to treat Huntington's disease. The safety and reliability of the RNA delivery system for the treatment of Huntington's disease have been fully verified. The system has good medicinal properties, strong versatility, and has economic benefits and application prospects.

Abstract: Provided are a viral vector-based RNA delivery system and a use thereof. The RNA delivery system comprises a viral vector. The viral vector carries an RNA fragment needing to be delivered, and can be enriched in organ tissues of a host. In the host organ tissues, the viral vector can endogenously and spontaneously form a composite structure containing the RNA fragment. The composite structure can enter and bind to target tissues, and feed the RNA fragment into the target tissues. The viral vector has a targeting tag. The composite structure is an exosome. The viral vector RNA delivery system is safe and reliable, and has good druggability and high universality.

Abstract: A method for assessing microbial drug resistance multi-level risks of antibiotic residues in water environments, belonging to the technical field of water environment assessment, comprises the following steps: S1, environment monitoring; S2, preliminary screening of antibiotics: S2-1, determination of n-octanol/water partition coefficient, and S2-2, determination of antibiotic environment concentration; S3, assessment of microbial drug resistance; and S4, high-level assessment. The assessment method of the present disclosure conducts a step-by-step assessment of target antibiotics or target antibiotic derivatives in water environment with risks.

Abstract: A method for assessing microbial drug resistance multi-level risks of antibiotic residues in water environments, belonging to the technical field of water environment assessment, comprises the following steps: S1, environment monitoring; S2, preliminary screening of antibiotics: S2-1, determination of n-octanol/water partition coefficient, and S2-2, determination of antibiotic environment concentration; S3, assessment of microbial drug resistance; and S4, high-level assessment. The assessment method of the present disclosure conducts a step-by-step assessment of target antibiotics or target antibiotic derivatives in water environment with risks.

Abstract: The present invention relates to S53 proteases and to the use of S53 protease in processes for converting starch to ethanol.

Abstract: S53 proteases and the use of S53 protease in processes for converting starch to ethanol are provided.

Abstract: Improved processes for producing ethanol from starch-containing materials by the combined use of at least one endoprotease and at least one exo-protease in an SSF process are disclosed. More particularly the exo-protease should make up at least 5% (w/w) of the protease mixture.

Abstract: S53 proteases and the use of S53 protease in processes for converting starch to ethanol are provided.